Clinical trials: Locally Advanced Tumors
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Advanced Solid Tumors
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the tolerability and safety profile and to characterize the pharmacokinetic profile of ASP8374 in Japanese patients with locally advanced (unresectable) or metastatic solid tumors.
- Trial name
- NCT03945253
- Testing
- ASP8374
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Astellas Pharma Inc
HER2-positive Metastatic Breast Cancer
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
This is an open-label, multicenter, dose-escalation and parallel-group expansion Phase II clinical trial to evaluate the efficacy, safety and tolerability of KN026 in combination with palbociclib and fulvestrant in women or male…
- Trial name
- NCT04778982
- Testing
- KN026 combined with Palbociclib and Fulvestrant
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
An international, multicenter, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of GenSci145, as monotherapy or in combination therapy, in participants with…
- Trial name
- NCT07407504
- Testing
- GenSci145 tablets
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Unresectable Locally Advanced Pancreatic Carcinoma
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy regulatory requirements.
- Trial name
- PanCO (NCT03003078)
- Testing
- OncoSil™
- Where
- 12 sites in Australia, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- OncoSil Medical Limited
Advanced Bladder Carcinoma
OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer
This Ⅱ study evaluates the safety and efficacy of intratumoral injection of OH2 in locally advanced or metastatic bladder cancer.
- Trial name
- NCT05248789
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Breast Cancer
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of-concept study of GDC-0810 as a single agent and in combination with palbociclib and/or LHRH agonist.
- Trial name
- NCT01823835
- Testing
- GDC-0810, LHRH Agonist, Palbociclib
- Where
- 14 sites in United States, Netherlands and 2 more
- Volunteers
- 152 people
- Sponsor
- Genentech, Inc.
HR+HER2- Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after…
- Trial name
- NCT06343948
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 383 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumors
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit.
- Trial name
- TITAN (NCT03454243)
- Testing
- RXDX-106
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT02572687
- Testing
- Ramucirumab, MEDI4736
- Where
- 28 sites in United States, France and 6 more
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with…
- Trial name
- NCT06382116
- Testing
- BL-B01D1, Pemetrexed+Cisplatin or Carboplatin
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
- Conditions
- Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- HERIZON-GEA-01 (NCT05152147)
- Testing
- Zanidatamab, Tislelizumab, Trastuzumab
- Where
- 227 sites in Argentina, Australia and 31 more
- Volunteers
- 920 people
- Sponsor
- Jazz Pharmaceuticals
Non-small Cell Lung Cancer Stage III
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in patients with unresectable EGFR-mutated Stage III non-small…
- Trial name
- NCT07640789
- Testing
- BL-B01D1, Osimertinib
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in…
- Trial name
- ELEVATE TNBC (NCT04958785)
- Testing
- Magrolimab, Nab-Paclitaxel, Paclitaxel
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
NSCLC
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
This study was a parallel, randomized, multicenter phase II clinical trial to evaluate the efficacy and safety of TY-9591 combined with platinum-based chemotherapy as first-line treatment in patients with locally advanced or…
- Trial name
- NCT06672068
- Testing
- TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin, TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin
- Volunteers
- 60 people
- Sponsor
- TYK Medicines, Inc
Breast Neoplasms
Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
The purpose of this study is to evaluate the safety and efficacy of pegylated liposomal doxorubicin (Caelyx) in elderly patients who are to receive first-line chemotherapy for metastatic or locally advanced breast cancer, not…
- Trial name
- NCT00604968
- Testing
- Caelyx (pegylated liposomal doxorubicin; SCH 200746)
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
This study is designed to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day (QOD) and Once Weekly (QW) dosing schedules.
- Trial name
- NCT01071018
- Testing
- MK2206 every other day, MK2206 once weekly
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer, Gastric Cancer
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03724851
- Testing
- TEW-7197
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- MedPacto, Inc.
Non-small Cell Lung Cancer
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X…
- Trial name
- NCT05168566
- Testing
- Sutetinib Maleate Capsule
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Teligene US
Pancreatic Carcinoma
CEB-01 in Locally Resectable Pancreatic Cancer
The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent.
- Trial name
- NCT06538857
- Testing
- Standard surgery, CEB-01
- Where
- 4 sites in Spain
- Volunteers
- 39 people
- Sponsor
- CEBIOTEX
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.